Trial Outcomes & Findings for VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C (NCT NCT02823457)
NCT ID: NCT02823457
Last Updated: 2022-01-18
Results Overview
Number of participants who completed treatment
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
20 participants
Primary outcome timeframe
12 weeks after initiation treatment
Results posted on
2022-01-18
Participant Flow
Participant milestones
| Measure |
VBMI Intervention Group
All patients will receive a 12 week VBMI intervention to promote treatment completion
VBMI: 12 week values based motivational interviewing intervention with a licensed psychologist
|
|---|---|
|
Overall Study
STARTED
|
20
|
|
Overall Study
COMPLETED
|
15
|
|
Overall Study
NOT COMPLETED
|
5
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C
Baseline characteristics by cohort
| Measure |
VBMI Intervention Group
n=20 Participants
All patients will receive a 12 week VBMI intervention to promote treatment completion
VBMI: 12 week values based motivational interviewing intervention with a licensed psychologist
|
|---|---|
|
Age, Continuous
|
65.0 years
STANDARD_DEVIATION 6.0 • n=93 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=93 Participants
|
|
Sex: Female, Male
Male
|
20 Participants
n=93 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=93 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=93 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=93 Participants
|
|
Race (NIH/OMB)
Black or African American
|
17 Participants
n=93 Participants
|
|
Race (NIH/OMB)
White
|
3 Participants
n=93 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=93 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=93 Participants
|
|
Region of Enrollment
United States
|
20 participants
n=93 Participants
|
PRIMARY outcome
Timeframe: 12 weeks after initiation treatmentNumber of participants who completed treatment
Outcome measures
| Measure |
VBMI Intervention Group
n=20 Participants
All patients will receive a 12 week VBMI intervention to promote treatment completion
VBMI: 12 week values based motivational interviewing intervention with a licensed psychologist
|
|---|---|
|
Treatment Completion
|
15 Participants
|
SECONDARY outcome
Timeframe: an average of 3 months after treatment completionNumber of participants who achieved SVR
Outcome measures
| Measure |
VBMI Intervention Group
n=20 Participants
All patients will receive a 12 week VBMI intervention to promote treatment completion
VBMI: 12 week values based motivational interviewing intervention with a licensed psychologist
|
|---|---|
|
Sustained Virologic Response
|
19 Participants
|
Adverse Events
VBMI Intervention Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place